Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  pamidronate disodium
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-20 of 20 for your search:
Start Over
The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Supportive care
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 2011349-01H, NCT01907880
Phase III Randomized Study of Zoledronate Versus Pamidronate in Patients With Cancer-Related Bone Lesions Due to Multiple Myeloma or Breast Cancer
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NOVARTIS-4244603010, UCLA-9911015
Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: CDR0000069274, U10CA021115, E-E1A00, E1A00, NCT00033332
Phase III Study of the Effect of Bisphosphonate APD on Morbidity Caused by Enhanced Bone Resorption in Stage II/III Multiple Myeloma (Summary Last Modified 12/89)
Phase: Phase III
Type: Supportive care
Status: Closed
Age: 20 to 75
Sponsor:
Protocol IDs: DUT-KWF-CKVO-8414, DUT-IKA-851
Phase III Randomized, Double-Blind Study of Gallium Nitrate vs Disodium Pamidronate (APD) in Patients with Cancer-Related Hypercalcemia (Summary Last Modified 03/90)
Phase: Phase III
Type: Supportive care
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: FRE-IGR-T89-0069, NCI-T89-0069A, T89-0069
Phase III Randomized, Placebo-Controlled Study of Pamidronate by 4-Hour Infusion for the Prevention of Skeletal-Related Episodes in Multiple Myeloma Patients with Osteolytic Lesions
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: CG-AREDIA-12, NCI-V92-0039
Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000546769, P30CA015083, MC048B, 261-05, MAYO-MC048B, MAYO-IRB-261-05, NCT00482378
Phase II Randomized, Double-Blind Study of Zoledronate vs Pamidronate for the Prevention of Skeletal-Related Episodes in Multiple Myeloma or Breast Cancer Patients with Osteolytic Bone Metastases (Summary Last Modified 11/97)
Phase: Phase II
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: UCLA-HSPC-960628101, NCI-V96-0975
Phase II Randomized Study of Zoledronate or Pamidronate in Patients with Tumor Induced Hypercalcemia (Summary Last Modified 12/1999)
Phase: Phase II
Type: Supportive care
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: NOVARTIS-4244604037, CGP-42446, NCI-V98-1413
Combination Chemotherapy, Peripheral Stem Cell Transplantation, Biological Therapy, Pamidronate and Thalidomide in Treating Patients With Multiple Myeloma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 65 and under
Sponsor: NCI, Other
Protocol IDs: 99021, P30CA033572, CHNMC-IRB-99021, NCI-G99-1583, CDR0000067301, NCT00004088
Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: Physiologic age 60 or under
Sponsor: NCI, Other
Protocol IDs: 98096, U01CA063265, P30CA033572, CHNMC-IRB-98096, CHNMC-PHII-18, NCI-H99-0038, CDR0000067305, IRB 98096, NCT00004092
Phase II Neoadjuvant/Adjuvant Study of Pamidronate With Standard Induction and Maintenance Chemotherapy in Patients With Newly Diagnosed High-Grade Osteosarcoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: Any age
Sponsor: NCI
Protocol IDs: MSKCC-03074, NCT00072306
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UARK 98-036, NCT00083382
Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: UARK 99-016, NCT00083408
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Women With Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: NCI, Other
Protocol IDs: NU-H97B1, CDR0000067586, NCI-G00-1682, NCT00004906
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-03082, PHI-45, U01CA062505, CDR0000434807, CCC-PHI-45, 6458, NCI-6458, NCT00124605
Randomized Placebo-Controlled Study of Pamidronate for the Prevention of Skeletal-Related Complications in Patients with Breast Cancer and Lytic Bone Lesions Treated with Hormonal Therapy
Phase: No phase specified
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: CG-AREDIA-18, NCI-V92-0040
Randomized Placebo-Controlled Study of Pamidronate for the Prevention of Skeletal-Related Complications in Patients with Breast Cancer and Lytic Bone Lesions Treated with Chemotherapy
Phase: No phase specified
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: CG-AREDIA-19, NCI-V92-0041
Investigation of Changes in Bone Scan Imaging Before and After Intravenous Bisphosphonate Therapy for Osseous Metastases From Breast Cancer
Phase: No phase specified
Type: Diagnostic, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 05-133, NCT00582920
Start Over